AIDX earnings analysis
What we found in AIDX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include current-period income-statement, balance-sheet, cash-flow, or segment figures, so revenue, margins, EPS, free cash flow, and period-over-period trends cannot be assessed. The principal disclosure is that controls remained ineffective as of June 30, 2026 because of 2 material weaknesses, with management unable to assure timely or successful remediation. The company also issued 40,798 shares in aggregate to service providers during the quarter and provided no quantitative guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Remediation efforts continued
- Management continued remediation during the second quarter of fiscal 2026, including formalizing control documentation, strengthening supervisory reviews, and hiring or engaging additional accounting and finance resources.
- Service-provider equity issuances
- The company issued 37,129 common shares to a service provider on April 7, 2026 and 3,669 shares to a service provider on April 27, 2026; no underwriters were involved.
- No share repurchases
- The company reported zero share repurchases during the three months ended June 30, 2026.
- Management affirms GAAP presentation
- Management stated that the consolidated financial statements fairly represent the company’s financial condition, results of operations, and cash flows as of and for the periods presented in accordance with GAAP.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective disclosure controls
- Disclosure controls and procedures were deemed ineffective as of June 30, 2026 because of 2 material weaknesses involving insufficient trained personnel, formal accounting controls, segregation of duties, and GAAP expertise.
- Restatement and reporting risk
- Management said it cannot assure that remediation will resolve the 2 material weaknesses in a timely manner or at all, or prevent future restatements. Failure to remediate could impair reporting accuracy and timing and could cause the common-stock market price to decline.
- Equity dilution exposure
- The company issued 37,129 shares on April 7, 2026 and 3,669 shares on April 27, 2026 to service providers, increasing the potential for equity dilution; the filing also identifies multiple outstanding warrants in Exhibits 4.2 through 4.9.
What they said about what is next.
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. Numeric outlook was not provided.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 20, 2026
- 20/20 Biolabs experienced a significant revenue decline of 36.19% year-over-year in Q1 2026, with total revenue of $353,375 and a net loss of $2,174,836, a substantial drop from the loss of $764,577 in Q1 2025.…
- 10-K · March 31, 2026
- 20/20 Biolabs (AIDX) is an early-stage diagnostics company selling its OneTest family (primarily OneTest for Cancer) from a CLIA/CAP lab; OneTest for Cancer made ~88% of revenue in 2025. The company reported FY2025…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AIDX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever